Marker Therapeutics, Inc.

Monthly Archives: November 2014

TapImmune CEO Discusses Company’s Clinical Programs in Recent Print and Radio Interviews

…In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement from phase 1 to phase 2 trials

SEATTLE, Nov. 24, 2014 /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed.

Read More

TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

…Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design

SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune’s proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

Read More